Vertex Pharmaceuticals (VRTX) Non-Current Debt (2009 - 2016)

Vertex Pharmaceuticals' Non-Current Debt history runs 6 years deep, the most recent figure standing at $74.9 million for Q2 2016.

• On a quarterly basis, Non-Current Debt fell 70.26% year-over-year to $74.9 million in Q2 2016; TTM through Jun 2016 was $74.9 million, a 70.26% decrease from a year earlier, with the FY2015 full-year figure at $223.9 million, down 20.21% from the prior year.
• Non-Current Debt retreated to $74.9 million in Q2 2016 per VRTX's latest filing, from $149.6 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $294.8 million in Q3 2015 and bottomed at $74.9 million in Q2 2016.
• The 3-year median for Non-Current Debt is $259.1 million (2015), against an average of $229.6 million.
• Across the five-year window, Non-Current Debt rose 0.03% in 2015 and tumbled 70.26% in 2016, its largest moves.
• Year by year, Non-Current Debt stood at $280.6 million in 2014, then retreated by 20.21% to $223.9 million in 2015, then tumbled by 66.53% to $74.9 million in 2016.
• Per Business Quant, the three latest VRTX Non-Current Debt figures stand at $74.9 million (Q2 2016), $149.6 million (Q1 2016), and $223.9 million (Q4 2015).